About Dr. Liu Tianshu
Dr. Liu Tianshu (刘天舒) is one of China's most distinguished medical oncologists and the Director of the Department of Medical Oncology at Zhongshan Hospital, affiliated with Fudan University. He holds the title of Chief Physician and Professor and is nationally recognized as a leading authority on gastrointestinal oncology, particularly colorectal cancer, gastric cancer, and hepatocellular carcinoma systemic therapy.
Over a career spanning more than two decades at the forefront of Chinese oncology, Dr. Liu has established Zhongshan Hospital's Medical Oncology Department as one of the premier gastrointestinal cancer treatment centers in China. He is particularly renowned for his expertise in colorectal cancer systemic therapy, conversion therapy for unresectable metastatic colorectal cancer, and immunotherapy for gastrointestinal cancers — areas where his contributions have shaped national clinical guidelines and influenced oncology practice across China.
International patients with colorectal cancer, gastric cancer, liver cancer, or other gastrointestinal malignancies seeking systemic therapy in China consistently identify Dr. Liu as one of the country's top medical oncologists for both primary treatment and expert second opinions.
Professional Positions and Affiliations
- Director, Department of Medical Oncology, Zhongshan Hospital, Fudan University
- Chairman, Colorectal Cancer Systemic Therapy Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chairman, Chinese Society of Clinical Oncology (CSCO)
- Editorial Board Member: Journal of Clinical Oncology, Annals of Oncology, Cancer
- Member, American Society of Clinical Oncology (ASCO)
- Member, European Society for Medical Oncology (ESMO)
Specialties and Clinical Expertise
- Colorectal Cancer Systemic Therapy — FOLFOX, FOLFIRI, FOLFOXIRI combinations; targeted therapy (bevacizumab, cetuximab, panitumumab based on RAS/BRAF status); immunotherapy (pembrolizumab, nivolumab for MSI-H/dMMR tumors); BRAF V600E-targeted therapy (encorafenib + cetuximab); HER2-targeted therapy for HER2-amplified colorectal cancer
- Conversion Therapy for Unresectable Colorectal Cancer — intensive chemotherapy plus targeted therapy or immunotherapy to convert initially unresectable liver metastases or locally advanced primary tumors to resectable; close collaboration with Dr. Xu Jianmin's colorectal surgery team
- Gastric and Gastroesophageal Junction Cancer — perioperative chemotherapy (FLOT, XELOX); HER2-targeted therapy (trastuzumab, trastuzumab deruxtecan); PD-1 inhibitor combinations (nivolumab, pembrolizumab); VEGFR2-targeted therapy (ramucirumab)
- Hepatocellular Carcinoma (HCC) Systemic Therapy — sorafenib, lenvatinib, atezolizumab/bevacizumab, sintilimab/bevacizumab; second-line therapy (regorafenib, cabozantinib, ramucirumab); combination with TACE and ablation
- Pancreatic Cancer — FOLFIRINOX, gemcitabine/nab-paclitaxel; PARP inhibitor maintenance for BRCA-mutated pancreatic cancer; clinical trial access for novel agents
- Precision Oncology and Biomarker-Driven Therapy — comprehensive genomic profiling (NGS), tumor mutational burden (TMB), microsatellite instability (MSI), and liquid biopsy for treatment selection and monitoring
- Immunotherapy Management — immune-related adverse event (irAE) recognition and management; immunotherapy rechallenge decisions
Academic and Research Contributions
Dr. Liu Tianshu has published over 180 peer-reviewed papers in leading international oncology journals, with a particular focus on conversion therapy for metastatic colorectal cancer, biomarker-driven treatment selection, and immunotherapy for gastrointestinal cancers. He has served as China Principal Investigator for multiple pivotal Phase III trials that led to regulatory approval of pembrolizumab, nivolumab, and encorafenib/cetuximab in China, bringing these transformative therapies to Chinese patients.
He chairs the Colorectal Cancer Systemic Therapy Committee of CSCO and has been a lead author on China's national colorectal cancer medical oncology guidelines. He is a regular invited speaker at ASCO, ESMO, and the CSCO annual congress, and serves on the editorial board of the Journal of Clinical Oncology.
Why International Patients Choose Dr. Liu Tianshu
- China's leading GI medical oncologist — Chairman of CSCO colorectal cancer systemic therapy committee
- Conversion therapy expertise — working hand-in-hand with Dr. Xu Jianmin's surgical team for unresectable colorectal cancer
- Journal of Clinical Oncology editorial board — at the forefront of global oncology research
- Clinical trial access — novel agents and combinations not yet commercially available
- Precision oncology — comprehensive NGS-guided treatment selection
- ASCO and ESMO member — aligned with international oncology standards
- English-language support available through CMCS concierge coordination
Practical Information for International Patients
- Hospital: Zhongshan Hospital, 180 Fenglin Road, Xuhui District, Shanghai
- Appointment Lead Time: 2″4 weeks; urgent cases expedited through CMCS
- Languages: Mandarin Chinese; English interpretation provided by CMCS
- Pre-consultation: Overseas pathology, NGS reports, and prior treatment records reviewed remotely through CMCS
How CMCS Can Help
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking oncology care with Dr. Liu Tianshu at Zhongshan Hospital. Our services include priority appointment booking, medical record and pathology translation, remote pre-consultation review, on-site interpretation, accommodation coordination, insurance liaison, clinical trial eligibility assessment, and post-treatment follow-up with your home country oncologist.
📧 Contact us: contract@medicalsh.com
🌐 medicalsh.com
0 comentarios